Cancer Treatment

L.E.I.S.H.

The LESIH procedure relies on the use of a proprietary LASER System, of a wavelength not significantly absorbed by human tissue and emitting a low power broad beam. It is a form of fractionated Photo-dynamic Therapy.

Both Photo-dynamic Therapy and Radio-fractionated Hyperthermia are FDA approved; however, due to limitations in the available delivery equipment, they cannot be utilized to treat larger tumors.

The LAILT System I, proprietary of LASE MED, Inc. and utilized in the delivery of the L.I.E.S.H. Therapy, is designed to handle any size of tumor.

LMI’s therapy relies on the use of injectable enchancer which is directly injected into the tumor and spreads thorughout it. This OxyM, which is water soluble and completely innocuous, in other words with the same side-effects of a saline solution.

This is an experimental modality that has become a part of "alternative" medical approach. There are no recent publications to suport it and the proprietry system has not been FDA approved, even as a technology. Afsaneh Bakhshandeh, Volker Bath, Gunter J Wiedemann, Walter Longo, Benjamin M Lerner, Cynthia L Tiggelaar, and H Ian Robins Year 2000 guidelines for clinical practice of whole body hyperthermia combined with cytotoxic drugs Journal of Oncology Pharmacy Practice, Vol. 5, No. 3, 131-134 (1999)from the University of Lübeck and the University of Wisconsin

Lagendijk JJ, Van Rhoon GC, Hornsleth SN, Wust P, De Leeuw AC, Schneider CJ, Van Dijk JD, Van Der Zee J, Van Heek-Romanowski R, Rahman SA, Gromoll C.
University Hospital Utrecht, The Netherlands.
ESHO quality assurance guidelines for regional hyperthermiaInt J Hyperthermia. 1998 Mar-Apr;14(2):125-33.

Insulin Potentiation Therapy

Insulin potentiation therapy (IPT) refers to the use of insulin along with lower doses of chemotherapy to treat cancer. It is also sometimes used with other types of treatments for chronic diseases.

IPT was developed in Mexico by Dr. Donato Perez Garcia, Sr., around the same time insulin had begun to be used in schizophrenics. In fact, some of those who support IPT note that, at this early stage, patients with cancer were also put into an insulin coma. Dr. Perez used this technique to try to treat several types of cancer. His son, Donato Perez Garcia Bellon, and grandson, Donato Perez Garcia, Jr., have followed in his footsteps. A physician from the United States, Dr. Steven G. Ayre, is a supporter of IPT and has published some descriptions of the theory behind it.

One very small published study that looked at IPT was done in Uruguay. It included 30 women with breast cancer that was resistant to mainstream therapies. Of these women, 10 got insulin alone, 10 got methotrexate (a chemotherapy drug) alone, and 10 received IPT using both drugs. After 8 weeks, the researchers reported that the women in the IPT group had smaller increases in tumor size than either of the other groups. Even though they used lower doses of methotrexate than usual, there were some side effects (mouth sores) noted in the IPT group. This study did not look at survival, quality of life, well being, or lasting effects. No long-term improvements were shown by this study.

Most of the information about IPT comes from individuals (anecdotal reports.) Even among these, however, there is no evidence that the people who report being helped by IPT were followed up long enough to find out if the treatment worked.

There are also concerns about using lower doses of chemotherapy drugs. When chemotherapy drugs are tested in clinical trials, their effects are carefully monitored to learn which dose will have most effect on the cancer while keeping the side effects as low as possible. There is no evidence that chemotherapy at a fraction of the recommended (tested) dose can produce the same effect as the full dose if insulin is used with it.

1. Ayre SG, et al. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer. Med Hypotheses. 2000 Oct;55(4):330-4.
2. Leroith D, Roberts C. The insulin-like growth factor system and cancer. Cancer Lett. 2003 ;195(2):127-37.
3. Benini S, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. 2001 ;7(6):1790-7.
4. Ayre SG, et al. Insulin potentiation therapy: a new concept in the management of chronic degenerative disease. Med Hypotheses. 1986 ;20(2):199-210.
5. Ayre SG, et al. Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas. Eur J Cancer. 1990;26(11-12):1262-3.
6. Albaster O, et al. Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol. 1981 ;(11):1223-8.
7. Holdaway IM, Friesen HG. Hormone binding by human mammary carcinoma. Cancer Res. 1977;37(7 Pt 1):1946-52.
8. Renehan AG, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;263: 1346-53.

top

---

Immunoaugmentative therapies

The treatment described is in the province of alternative medicine and not allopathic medicine. The theory for teht reatment that is described does not 'fit' allopathic physiology.

Immuno-Technologies Cancer Clinic (ITL) is located 30 minutes (by plane) from Miami in Freeport, Bahamas. The Clinic and the alternative cancer treatment research center is directed by Dr. John Clement.

Each alternative cancer treatment plan is customized to the person with cancer. In addition to immune therapy such as cancer vaccine we provide angiogenesis inhibition (blocking new blood vessels that feed tumor), apoptosis inducing agents (help tumor cells to commit suicide), and cytotoxic agents that kill tumor cells while not destroying normal cells, including photodynamic therapy (a dye made from chlorophyll accumulates in the tumor, and a light is applied to activate the dye to kill the tumor).
Immuno-augmentative therapy (IAT) was developed by Lawrence Burton, Ph.D., a zoologist who claimed that it could control all forms of cancer by restoring natural immune defenses. He claimed to accomplish this by injecting blood serum proteins isolated with processes he had patented. However, experts have shown that the substances he claimed to use cannot be produced by these procedures and do not exist in the human body. Burton did not publish detailed clinical reports, divulge the details of his methods, publish meaningful statistics, conduct a controlled trial, or provide independent investigators with specimens of his treatment materials for analysis. During the mid-1980s, several of Burton's patients were reported to have developed serious infections following IAT. Burton died in 1993, but the Bahamian clinic he founded is still operating under the direction of Dr. R. John Clement, a British-trained general practitioner who joined with Burton in 1978.

No evidence has been published showing that immuno-augmentative therapy is safe or effective against cancer in humans. Burton did not publish detailed clinical reports or meaningful statistics, divulge the details of his methods, conduct a controlled trial, or provide independent investigators with specimens of his treatment materials for analysis. The mechanism of action he postulated for his treatment involved substances that are unknown to the scientific community. Although Burton said that IAT treatment materials were produced with processes he patented, experts do not believe that these processes can achieve what he claimed. Several attempts to develop a protocol for a clinical trial of IAT were unsuccessful. Moreover, during the mid-1980s, cases were reported of patients of Burton who developed serious infections following IAT.

"After studying the literature and other available information, the American Cancer Society has found no evidence that the "immuno-augmentative therapy (IAT)" advocated by Lawrence Burton, PhD, is safe or results in objective benefit in the treatment of cancer. Lacking such evidence, the American Cancer Society strongly urges individuals with cancer not to seek such treatment." (CA 1991)

A 2003 review of patient cases concluded that the treatment is ineffective.

Spencer JW, Jacobs JJ. Complementary/alternative medicine: an evidence based approach. Toronto: Mosby, 1999:149.

Bernd L. Pfeifer, MD, PhD  Wayne B. Jonas, MD
Clinical Evaluation of "Immunoaugmentative Therapy (IAT)": An Unconventional Cancer Treatment Integrative Cancer Therapies, Vol. 2, No. 2, 112-119 (2003)